echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > PNAs: intratumoral injection of influenza vaccine can significantly enhance anti-cancer immunotherapy

    PNAs: intratumoral injection of influenza vaccine can significantly enhance anti-cancer immunotherapy

    • Last Update: 2020-02-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    February 19, 2020 / Biovalley BIOON / -- PD-1 checkpoint inhibitor is more effective in immunoinfiltrating "hot" cancer than in immunomild "cold" cancer Therefore, it is an important direction of immunooncology to develop a method to transform cancer from cold to hot Antiviral response provides a possible way to "start" tumor immune infiltration Intratumoral injection of antiviral pattern recognition pathway agonists can promote acute inflammation These drugs are currently in clinical trials, with mixed success or failure Photo source: https://cn.bing.com/newman et al Now report a study using direct intratumoral influenza vaccine to promote immune cells to infiltrate tumors They point out that cancer-specific mortality in lung cancer patients with influenza is low, and they also hypothesize that exposure to influenza viruses may increase the immune infiltration of patients' tumors In a mouse model of melanoma with lung metastasis, they observed that nasal administration of an active influenza virus reduced the formation of lung metastases Injection of influenza virus into the tumor reduced the size of the tumor and increased the immune infiltration of dendritic cells (DC) and T cells These experiments were carried out with commercial inactivated vaccine, which has synergistic effect with PD-1 inhibition Interestingly, in their mouse models, tumor immunosuppression regulates the depletion of B cells, which is crucial for their antitumor effect When vaccinated in the tumor, the mice also retained the ability to provide anti influenza protection Based on these findings, the authors suggest that injecting a clinically approved influenza vaccine into a tumor to an accessible metastatic tumor will have dual benefits, providing anti influenza protection and anti-cancer immune infiltration This is a thought-provoking idea that can be easily translated into clinical trials However, to choose the right clinical environment to test the influenza injection, we need to answer some key questions first Given that the "cold" state of the immune system is caused by a variety of different immunosuppressive pathways, is the "cancer flu vaccine" effective only for those cold tumors that play a leading role in regulatory B cells? Is there genetic variation in cancer that promotes or suppresses response to influenza virus components? If they exist, can they be used as biomarkers of therapeutic sensitivity? Does simultaneous injection of virus components and PD-1 inhibitors aggravate immunotoxicity? Further validation in a carefully selected immune robust cancer model will help answer these questions Nevertheless, the safety of existing influenza vaccines provides an attractive choice for the simple transformation of cancer from "cold" to "hot" Reference: zloza, internal et al Injection of the seasonal flu shot conversions immunologically cold tutorials to hot and services as an immutability for cancer Proc Natl Acad SCI U.S.A (2019) Doi: 10.1073/pnas.1904022116
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.